TIDMHIK
RNS Number : 4627Z
Hikma Pharmaceuticals Plc
17 May 2019
Hikma Pharmaceuticals PLC
Voting Results of 2019 Annual General Meeting
LONDON, 17 May 2019 - Hikma Pharmaceuticals PLC (the "Company")
announces its Annual General Meeting ("AGM"), held at Sofitel St
James, 6 Waterloo Place, London SW1Y 4AN on 17 May 2019 commenced
at 10:00 am. All resolutions were duly passed by shareholders by
way of a poll. Resolutions 1 to 16 were passed as ordinary
resolutions and Resolutions 17 to 20 were passed as special
resolutions.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the National Storage Mechanism
and will shortly be available for inspection at
www.morningstar.co.uk/uk/nsm
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 15 April 2019) is set out below. The number of Ordinary
Shares in issue on 17 May 2019 was 242,013,996.
Resolution Votes For % Votes Against % Total Cast Withheld
1. To receive the
2018 report and
accounts 198,016,257 99.99 15,248 0.01 198,031,505 145,325
------------ ------- -------------- ------ ------------ ---------
2. To approve a
final dividend of
26 cents per share 198,172,485 100.00 437 0.00 198,172,922 3,909
------------ ------- -------------- ------ ------------ ---------
3. To re-appoint
PricewaterhouseCoopers
LLP as auditors 198,168,429 100.00 2,171 0.00 198,170,600 6,231
------------ ------- -------------- ------ ------------ ---------
4.To authorise the
Audit Committee
to determine the
auditors' remuneration 198,169,496 100.00 1,989 0.00 198,171,485 5,346
------------ ------- -------------- ------ ------------ ---------
5. To re-elect Said
Darwazah as a director 191,458,492 96.61 6,712,792 3.39 198,171,284 5,546
------------ ------- -------------- ------ ------------ ---------
6. To re-elect Siggi
Olafsson as a director 194,921,594 98.36 3,251,178 1.64 198,172,772 4,059
------------ ------- -------------- ------ ------------ ---------
7. To re-elect Mazen
Darwazah as a director 191,501,356 96.63 6,670,679 3.37 198,172,035 4,796
------------ ------- -------------- ------ ------------ ---------
8. To re-elect Robert
Pickering as a director 186,397,645 94.06 11,763,463 5.94 198,161,108 15,722
------------ ------- -------------- ------ ------------ ---------
9.To re-elect Ali
Al-Husry as a director 189,606,735 95.68 8,564,549 4.32 198,171,284 5,546
------------ ------- -------------- ------ ------------ ---------
10. To re-elect
Patrick Butler as
a director 194,287,800 98.04 3,883,484 1.96 198,171,284 5,546
------------ ------- -------------- ------ ------------ ---------
11. To re-elect
Dr. Pamela Kirby
as a director 182,139,906 91.91 16,032,128 8.09 198,172,034 4,796
------------ ------- -------------- ------ ------------ ---------
12. To re-elect
Dr. Jochen Gann
as a director 194,395,430 98.09 3,775,854 1.91 198,171,284 5,546
------------ ------- -------------- ------ ------------ ---------
13. To re-elect
John Castellani
as a director 195,035,397 98.42 3,135,888 1.58 198,171,285 5,546
------------ ------- -------------- ------ ------------ ---------
14. To re-elect
Nina Henderson as
a director 194,490,204 98.14 3,681,830 1.86 198,172,034 4,796
------------ ------- -------------- ------ ------------ ---------
15. To approve the
remuneration report
for the year ended
31 December 2018 190,476,075 96.12 7,695,409 3.88 198,171,484 5,346
------------ ------- -------------- ------ ------------ ---------
16. Authority to
allot shares 168,835,150 85.20 29,337,771 14.80 198,172,921 3,909
------------ ------- -------------- ------ ------------ ---------
17. To dis-apply
pre-emption rights
for general purposes 198,116,024 99.97 56,161 0.03 198,172,185 4,646
------------ ------- -------------- ------ ------------ ---------
18. To dis-apply
pre-emption rights
for an acquisition
or other capital
investment 195,242,802 98.52 2,929,382 1.48 198,172,184 4,646
------------ ------- -------------- ------ ------------ ---------
19. To authorise
the Company to purchase
its own shares 197,396,007 99.66 682,740 0.34 198,078,747 98,083
------------ ------- -------------- ------ ------------ ---------
20. To authorise
the Company to hold
general meetings
on no less than
14 clear days' notice 187,234,093 94.48 10,936,803 5.52 198,170,896 5,785
------------ ------- -------------- ------ ------------ ---------
Declaration of final dividend
The dividend of 26 cents per share will be paid on 22 May 2019
to shareholders on the register on 5 April 2019. Shareholders who
are not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $1.2928 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at circa 1JD to
$1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
EVP, Strategic Planning and Global Affairs +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
LEI: 549300BNS685UXH4JI75
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGSFWFIWFUSESI
(END) Dow Jones Newswires
May 17, 2019 11:09 ET (15:09 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Mar 2023 to Mar 2024